Mumbai, April 28 -- Sun Pharmaceutical Industries on Monday announced the $11.75 billion acquisition of Organon & Co., in a seemingly aggressive push into the US market that has long decided the global fortunes of Indian drugmakers. However, the biggest buyout by an Indian company in nearly 20 years also signals that the US generics market's decades-long allure is beginning to fade for Indian drugmakers, which are now eyeing newer markets such as China, South Korea, and Spain with branded generics. Announced early on Monday, the Organon acquisition ranks as the second-largest acquisition by an Indian company, behind Tata Steel's 2007 deal to buy British steel maker Corus Group for $12 billion. For years, Indian pharma rode a powerful wave in the US, as expiring patents of blockbuster small-molecule drugs opened a gold mine for low-cost generic drug makers in the world's largest drug market. Companies like Dilip Shanghvi-led Sun Pharma built scale, profitability and global credibility by pushing into the US. Even today, the US contributes about 31% of Sun's revenues, second only to the Indian domestic market bringing 37%. The Organon buyout subtly but significantly alters that balance-once the deal concludes, India's share in the combined $12.4 billion revenues of Sun Pharma-Organon drops to 17%, while the US accounts for 27%. In absolute terms, US revenues will increase from $1.9 billion to $3.35 billion, or an incremental $1.4 billion. Organon revenues in 2025 stood at $6.2 billion. That mismatch underscores the deal's real intent-Shanghvi is not paying a premium to double down on the US. He is buying access-to markets, portfolios, and new therapeutic segments that lie beyond it, industry experts and analysts said....